Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1929卷 / 1期

关键词：

D O I：

10.1007/s40278-022-25983-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：359 / 359

相关论文

共 50 条

[21] Ipilimumab/nivolumabImmune mediated hepatitis: case report
[J]. Reactions Weekly, 2021, 1869 (1) : 193 - 193
[22] Ipilimumab/nivolumabDermatitis, diarrhoea and hepatitis: case report
[J]. Reactions Weekly, 2019, 1753 (1) : 202 - 202
[23] Ipilimumab/nivolumabImmune mediated hepatitis: case report
[J]. Reactions Weekly, 2019, 1757 (1) : 176 - 176
[24] Ipilimumab/nivolumabDermatitis, colitis and hepatitis: case report
[J]. Reactions Weekly, 2021, 1838 (1) : 288 - 288
[25] Ipilimumab/NivolumabGrade 1 hypothyroidism and grade 3 secondary adrenal insufficiency
[J]. Reactions Weekly, 2023, 1985 (1) : 272 - 272
[26] Hepatitis A vaccineFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2007, 1153 (1) : 14 - 14
[27] Ipilimumab/nivolumabSeronegative autoimmune autonomic ganglionopathy: case report
[J]. Reactions Weekly, 2019, 1780 (1) : 199 - 199
[28] Ipilimumab/nivolumab/pembrolizumabHypothyroidism and autoimmune thyroiditis: case report
[J]. Reactions Weekly, 2018, 1712 (1) : 313 - 313
[29] NivolumabGrade II hepatotoxicity: case report
[J]. Reactions Weekly, 2020, 1789 (1) : 194 - 194
[30] Ipilimumab/nivolumab/temozolomideWorsening of immune-related vitiligo, autoimmune hepatitis and acquired resistance: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 254 - 254

← 1 2 3 4 5 →